Cybin Inc (CYBN)

$8.58 +0.32 (3.87%)
Market Cap 190.18M
Revenue (ttm) 0.00
Net Income (ttm) -57.88M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 323,700
Avg Vol 297,522
Day's Range N/A - N/A
Shares Out 23.02M
Stochastic %K 92%
Beta 0.68
Analysts Strong Sell
Price Target $79.40

Company Profile

Cybin Inc., a clinical-stage biopharmaceutical company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 1/2a clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which completed phase 2 clinical trial for treating generalized anxiety disor...

Industry: Biotechnology
Sector: Healthcare
Address:
100 King Street West, Suite 5600, Toronto, Canada
Allergictobears
Allergictobears Jun. 27 at 1:52 PM
$CYBN gonna sell here prob as I think it will bounce off 200MA daily downward. might be wrong but wanna secure some profits. entire sector looks like could explode soon. but history has shown that news really means nothing in this sector. remember CMPS in 2021? released results early and fucked everyone over.
0 · Reply
microdoseme
microdoseme Jun. 27 at 12:39 AM
$CYBN https://www.msn.com/en-us/sports/nfl/on-the-brink-of-retirement-this-nfl-player-turned-to-psychedelics-to-help-with-his-ocd/ar-AA1Ho05t?ocid=socialshare
0 · Reply
NotSoSillyCybn
NotSoSillyCybn Jun. 27 at 12:35 AM
GO AWAY $CYBN
0 · Reply
microdoseme
microdoseme Jun. 26 at 7:58 PM
$CYBN Earnings on 7/3
1 · Reply
Bulltrader988
Bulltrader988 Jun. 26 at 7:12 PM
$MNMD added this basket today $CMPS $CYBN $MIRA 👃👀
0 · Reply
grumpygoose
grumpygoose Jun. 26 at 5:42 PM
$CYBN ??? No earnings I guess
1 · Reply
cacci11
cacci11 Jun. 26 at 4:43 PM
$ATAI $CMPS $CYBN whole sector is asleep at the wheel
0 · Reply
Mastacash
Mastacash Jun. 26 at 3:30 PM
$CYBN this stock can double and it would just be considered a catch up trade to sector peers. Then the evaluation can begin.
1 · Reply
CybinWTF
CybinWTF Jun. 26 at 3:08 PM
$CYBN no need to call out #DisasterDoug the past 2 days. Hope this trend continues, but I stand ready to revert, if necessary.
0 · Reply
cacci11
cacci11 Jun. 26 at 1:53 PM
$CYBN so many undervalued plays in the sector. There is willful suppression and skepticism going on, but it won’t hold up long with media pumping out positive vibes.
0 · Reply
Latest News on CYBN
Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Jun 13, 2025, 7:45 AM EDT - 14 days ago

Cybin Provides Corporate Update and Highlights Positive Regulatory Signals for Psychedelic Therapeutics

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Jun 12, 2025, 7:30 AM EDT - 15 days ago

Cybin to Participate in the H.C. Wainwright 6th Annual Neuro Perspectives Conference

Cybin to Participate in the 2025 Psychedelic Science Conference

Jun 11, 2025, 7:30 AM EDT - 16 days ago

Cybin to Participate in the 2025 Psychedelic Science Conference

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Jun 3, 2025, 7:30 AM EDT - 24 days ago

Cybin Announces Additional U.S. Patent Supporting its CYB004 Program in Phase 2 Development for Generalized Anxiety Disorder

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

May 22, 2025, 7:30 AM EDT - 5 weeks ago

Cybin to Participate in Water Tower Research Fireside Chat on May 29, 2025

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

May 20, 2025, 7:30 AM EDT - 5 weeks ago

Cybin Applauds FDA Commissioner Dr. Martin Makary's Call to Accelerate and Prioritize Research on Psychedelic Therapeutics

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

May 15, 2025, 7:30 AM EDT - 6 weeks ago

Cybin Engages Thermo Fisher Scientific to Provide U.S.-Based Manufacturing for its CYB003 Program for the Adjunctive Treatment of Major Depressive Disorder

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

May 14, 2025, 7:30 AM EDT - 6 weeks ago

Cybin to Participate in the Alliance Global Partners Healthcare Company Showcase

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

May 8, 2025, 7:30 AM EDT - 7 weeks ago

Cybin Announces Additional U.S. Patent Supporting its CYB003 Breakthrough Therapy Program in Phase 3 Development for Major Depressive Disorder

Cybin to Participate at the 28th Annual Milken Institute Global Conference

May 1, 2025, 7:30 AM EDT - 2 months ago

Cybin to Participate at the 28th Annual Milken Institute Global Conference

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Apr 23, 2025, 7:30 AM EDT - 2 months ago

Cybin Announces Additional Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Phase 3 Program Evaluating CYB003

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Apr 21, 2025, 8:00 AM EDT - 2 months ago

Cybin Partners with Osmind to Accelerate Commercial Preparation for its Clinical-Stage Psychiatry Programs

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Feb 10, 2025, 9:48 PM EST - 4 months ago

Cybin Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Jan 15, 2025, 12:07 PM EST - 5 months ago

Cybin Launches Strategic Clinical Site Partnerships to Support PARADIGM, a Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Jan 13, 2025, 7:30 AM EST - 5 months ago

Cybin Highlights 2024 Accomplishments and Upcoming Milestones for 2025

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 5:00 PM EST - 6 months ago

Cybin to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Dec 10, 2024, 7:30 AM EST - 7 months ago

Cybin Announces Poster Presentations at the 2024 American College of Neuropsychopharmacology Annual Meeting, Including CYB003 12-Month Efficacy Results

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Dec 4, 2024, 7:30 AM EST - 7 months ago

Cybin to Participate in Water Tower Research Fireside Chat on December 11, 2024

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Nov 18, 2024, 7:00 AM EST - 7 months ago

Cybin Reports Positive Phase 2 Data for CYB003, Demonstrating Breakthrough 12-Month Efficacy in Treating Major Depressive Disorder

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Nov 14, 2024, 7:30 AM EST - 8 months ago

Cybin to Present 12-Month Phase 2 Data for CYB003 in Major Depressive Disorder on November 18, 2024

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Nov 13, 2024, 7:30 AM EST - 8 months ago

Cybin Initiates PARADIGM: A Multinational Pivotal Phase 3 Program Evaluating CYB003 for the Adjunctive Treatment of Major Depressive Disorder and Reports Second Quarter Financial Results

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Oct 31, 2024, 7:30 AM EDT - 8 months ago

Cybin to Participate at the 2024 Milken Institute Future of Health Summit

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Oct 24, 2024, 7:30 AM EDT - 8 months ago

Cybin Announces Grant of First U.S. Composition of Matter Patent in Support of its CYB005 Phenethylamines Program

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

Oct 18, 2024, 2:30 PM EDT - 8 months ago

Undercovered Dozen: Endava, Cross Country Healthcare, Cybin, Equinor +

DAVA EQNR

Cybin: Top Value Psychedelic Stock

Oct 15, 2024, 12:30 PM EDT - 9 months ago

Cybin: Top Value Psychedelic Stock

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Oct 3, 2024, 7:30 AM EDT - 9 months ago

Cybin to Participate in Water Tower Research Fireside Chat on October 8, 2024

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Oct 1, 2024, 7:30 AM EDT - 9 months ago

Cybin Expands Clinical Team to Support CYB003 Phase 3 Program

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Sep 27, 2024, 11:48 AM EDT - 9 months ago

Water Tower Research Publishes Initiation of Coverage Report on Cybin, Inc., “A Leader in Novel Neuropsychiatry Therapeutics”

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Sep 24, 2024, 7:30 AM EDT - 9 months ago

Cybin to Participate in the TD Cowen 4th Annual Novel Mechanisms in Neuropsychiatry Summit

Cybin Provides Corporate Update on Upcoming Clinical Milestones

Sep 19, 2024, 5:38 PM EDT - 10 months ago

Cybin Provides Corporate Update on Upcoming Clinical Milestones

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Sep 19, 2024, 8:00 AM EDT - 10 months ago

'We're Pretty Cheap At The Moment' - Cybin CEO Doug Drysdale

Cybin Announces Completion of Previously Announced Share Consolidation

Sep 19, 2024, 7:26 AM EDT - 10 months ago

Cybin Announces Completion of Previously Announced Share Consolidation

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 7:55 AM EDT - 10 months ago

Cybin to Participate in the H.C. Wainwright 26th Annual Global Investment Conference

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Aug 27, 2024, 7:01 PM EDT - 10 months ago

Cybin Announces Results of Annual and Special Meeting of Shareholders and Share Consolidation

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

Aug 27, 2024, 5:00 PM EDT - 10 months ago

Inovalis Real Estate Investment Trust Provides Supplemental Information in Connection With Its Upcoming Special Meeting of Unitholders to Be Held on September 4, 2024

V

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Aug 13, 2024, 7:30 AM EDT - 11 months ago

Cybin Announces Completion of FDA Type B Initial Breakthrough Therapy Meeting and Plans for CYB003 Phase 3 Program in Major Depressive Disorder

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

Aug 12, 2024, 12:12 PM EDT - 11 months ago

Psychedelic drug contender stocks drop after FDA rejects MDMA treatment

ATAI CMPS MNMD

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Aug 8, 2024, 7:36 AM EDT - 11 months ago

Cybin Reports First Quarter Fiscal Year 2025 Financial Results and Recent Business Highlights

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

Aug 7, 2024, 7:30 AM EDT - 11 months ago

Cybin to Participate in the Canaccord Genuity 44th Annual Growth Conference

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Jul 8, 2024, 8:38 AM EDT - 1 year ago

A Swell Of Insider Purchases Follow Cybin Inc.'s Positive Year-End Update

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Jun 26, 2024, 7:41 AM EDT - 1 year ago

Cybin Reports Fiscal Year 2024 Financial Results and Recent Business Highlights

Cilo Cybin becomes first medical cannabis company to list in South Africa

Jun 25, 2024, 10:19 AM EDT - 1 year ago

Cilo Cybin becomes first medical cannabis company to list in South Africa

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Jun 19, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Jun 11, 2024, 7:30 AM EDT - 1 year ago

Cybin Appoints Dr. Atul Mahableshwarkar M.D., as Senior Vice President, Clinical Development

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

May 29, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the Pathways to Access Summit and the Interdisciplinary Conference on Psychedelic Research 2024

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

May 6, 2024, 8:32 AM EDT - 1 year ago

Cybin Provides Corporate Update and Highlights Upcoming Clinical Milestones

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Apr 25, 2024, 7:30 AM EDT - 1 year ago

Cybin to Participate at the 27th Annual Milken Institute Global Conference

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Apr 18, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Publication of Research Manuscript in the Journal of Medicinal Chemistry

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Apr 16, 2024, 7:30 AM EDT - 1 year ago

Cybin Announces Grant of Additional U.S. Patent in Support of its CYB003 Breakthrough Therapy Program for Major Depressive Disorder

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Apr 10, 2024, 7:30 AM EDT - 1 year ago

Cybin to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference

Allergictobears
Allergictobears Jun. 27 at 1:52 PM
$CYBN gonna sell here prob as I think it will bounce off 200MA daily downward. might be wrong but wanna secure some profits. entire sector looks like could explode soon. but history has shown that news really means nothing in this sector. remember CMPS in 2021? released results early and fucked everyone over.
0 · Reply
microdoseme
microdoseme Jun. 27 at 12:39 AM
$CYBN https://www.msn.com/en-us/sports/nfl/on-the-brink-of-retirement-this-nfl-player-turned-to-psychedelics-to-help-with-his-ocd/ar-AA1Ho05t?ocid=socialshare
0 · Reply
NotSoSillyCybn
NotSoSillyCybn Jun. 27 at 12:35 AM
GO AWAY $CYBN
0 · Reply
microdoseme
microdoseme Jun. 26 at 7:58 PM
$CYBN Earnings on 7/3
1 · Reply
Bulltrader988
Bulltrader988 Jun. 26 at 7:12 PM
$MNMD added this basket today $CMPS $CYBN $MIRA 👃👀
0 · Reply
grumpygoose
grumpygoose Jun. 26 at 5:42 PM
$CYBN ??? No earnings I guess
1 · Reply
cacci11
cacci11 Jun. 26 at 4:43 PM
$ATAI $CMPS $CYBN whole sector is asleep at the wheel
0 · Reply
Mastacash
Mastacash Jun. 26 at 3:30 PM
$CYBN this stock can double and it would just be considered a catch up trade to sector peers. Then the evaluation can begin.
1 · Reply
CybinWTF
CybinWTF Jun. 26 at 3:08 PM
$CYBN no need to call out #DisasterDoug the past 2 days. Hope this trend continues, but I stand ready to revert, if necessary.
0 · Reply
cacci11
cacci11 Jun. 26 at 1:53 PM
$CYBN so many undervalued plays in the sector. There is willful suppression and skepticism going on, but it won’t hold up long with media pumping out positive vibes.
0 · Reply
BankOnTheFuture
BankOnTheFuture Jun. 25 at 11:21 PM
$CMPS $CYBN $ATAI $MNMD HR3944 PASSED. "Department of Veterans Affairs to direct the Department to evaluate and make recommendations on changes that would need to be made to its existing healthcare infrastructure to integrate approved psychedelic therapies into veterans' care options for conditions such as PTSD and substance use disorders. " https://democraticwhip.house.gov/floor-resources/amendment-tracker/hr-3944-military-construction-veterans-affairs-and-related-agencies-appropriations-act-2026
0 · Reply
Hardspot
Hardspot Jun. 25 at 7:46 PM
$CYBN I wonder what Chuck Norris would think about this stock.
2 · Reply
Bulltrader988
Bulltrader988 Jun. 25 at 6:42 PM
$MNMD with $CMPS $CYBN $MIRA 👃👀 https://x.com/OracleNYSE/status/1937937998558986705?t=mwfWeATSjofS0Q06o4yNEw&s=19
0 · Reply
leLu83
leLu83 Jun. 25 at 5:21 PM
$CYBN You must understand that Svengali Dougs model is Dilution.
1 · Reply
leLu83
leLu83 Jun. 25 at 5:19 PM
$CYBN Dilution Doug is like a bull in china shop with shareholders' money.
0 · Reply
Rico_Again_Jorge
Rico_Again_Jorge Jun. 25 at 4:54 PM
$CYBN Please go to $10
0 · Reply
grumpygoose
grumpygoose Jun. 25 at 4:32 PM
$CYBN earnings AH today, probably a nothing burger but who knows
0 · Reply
twiggs462
twiggs462 Jun. 25 at 4:31 PM
$CMPS $ATAI $MNMD $CYBN
0 · Reply
UncleJudd
UncleJudd Jun. 25 at 2:28 PM
$CMPS $ATAI $MNMD $CYBN https://www.biospace.com/fda/fda-names-psychedelic-proponent-as-cder-deputy-director-top-spot-remains-open
0 · Reply
sam2680
sam2680 Jun. 25 at 11:31 AM
$CYBN https://finance.yahoo.com/news/cybin-granted-key-patent-cyb004-080857537.html
0 · Reply
DaytradeX
DaytradeX Jun. 25 at 8:17 AM
$ATAI $CMPS $CYBN $MNMD $PFE „ Stifel Says Compass Pathways Selloff Significantly Overdone After Psilocybin Trial Data „ https://stocktwits.com/news-articles/markets/equity/stifel-says-compass-pathways-selloff-significantly-overdone-after-psilocybin-trial-data/chmEzezRRdk
0 · Reply
Shabbaman
Shabbaman Jun. 25 at 2:25 AM
$CYBN 10 in the cards if the hype train keeps going!!
0 · Reply